Hot Investor Mandate 4: Corporate Venture Fund Invests in Therapeutics, Devices and HCIT for Cardiovascular Diseases, Pain, Kidney Diseases and More

14 Sep

A diversified business based in Japan has opened US corporate venture offices in Massachussets and California. The corporate venture fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. The firm seeks to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, cardiovascular disease, musculoskeletal disease, kidney disease, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. They generally request at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: